Full text loading...
- ISSN: 1875-6921
- E-ISSN: 1875-6913
-
Current Clinical Application and Response Prediction Biomarkers of PARP Inhibitors
- Source: Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Volume 16, Issue 2, Jun 2018, p. 108 - 117
-
- 01 Jun 2018
Abstract
Recently, novel drugs that inhibit the enzyme poly (ADP-ribose) polymerase (PARP) based on the concept of synthetic lethality are used for cancer treatment. Three PARP inhibitors (olaparib, rucaparib and niraparib) are approved for the treatment of recurrent ovarian cancer in the US or Europe, while another two (veliparib and talazoparib) showed promising anti-cancer activity. This review aims to summarize the current status of clinical trials on PARP inhibitors and then discusses studies aimed to identify biomarkers for predicting the efficacy of PARP inhibitors.
© Bentham Science Publishers